Kexing Biopharm obtained the products of Trastuzumab and Neratinib Maleate Tablets
Recently, Kexing Biopharm (688136.SH) signed with Chia-Tai Tianqing (CTTQ) an exclusive cooperation agreement for overseas commercialization of Trastuzumab for Injection recently. As a result, it has obtained the rights to commercialize the first batch of Trastuzumab for Injection in 12 countries. Meanwhile, Kexing has been signed with Convalife Pharmaceuticals a cooperation agreement for the international commercialization of Neratinib Maleate Tablets. Kexing Biopharm has obtained the rights to commercialize Convalife Pharmaceuticals’ Neratinib Maleate Tablets in six countries, including Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Egypt. These agreements not only further expands the pipeline of Kexing Biopharm’s antitumor products, but also showcases its strength in overseas commercialization.
CTTQ’s Trastuzumab biosimilar has been applied for marketing in China for treatement of metastatic breast cancer, early stage breast cancer, and metastatic gastric cancer. The drug can bind to HER-2 receptors and prevent EGF from rebinding to HER-2, thus slowing the growth of cancer cells. With excellent clinical performance, Trastuzumab has become a critical product in breast cancer treatment.
Neratinib Maleate Tablets are an oral irreversible small molecule pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI) indicated for the extended adjuvant treatment of adult patients with early-stage breast cancer who are human epidermal growth factor receptor 2-positive (HER2+), to follow adjuvant trastuzumab-based therapy.
With a product portfolio strategy focused on breast cancer, Kexing Biopharm has already secured important products like albumin-bound paclitaxel, trastuzumab, bevacizumab, and neratinib. As Kexing Biopharm’s product pipelines continue to improve, its market competitiveness has significantly strengthened, ensuring its position for sustainable future development with full confidence.
In recent years, Kexing Biopharm has accelerated the R&D of drugs for unmet clinical needs. Meanwhile, it has introduced high-value products with “Three Highs and One Fast” (high clinical value, high technical level, and high international quality management and registration standards; fast commercialization). The company remains committed to bringing more effective drugs worldwide, deeply cultivating the global pharmaceutical market, facilitating drug promotion, and benefiting more patients.
Kexing Biopharm Co., Ltd. (short for “Kexing Biopharm”, stock code: 688136) is an international innovative biopharmaceutical enterprise mainly engaged in the R&D, production, and sales of recombinant protein therapeutics and microecological agents. In recent years, the company keeps exploring the wide application of biotechnology in healthcare and actively fosters and incubates emerging industries. It has invested in world-leading industrial platforms concerning animal vaccines, synthetic biology, and bacteriophage. Kexing Biopharm strives to become a leader in high-quality biopharmaceutics and serve global patients.
Media Contact
Company Name: Kexing Biopharm Co., Ltd.
Contact Person: Chelsea Zheng
Email: Send Email
Country: China
Website: www.kexing.com
